Selecta Biosciences raises $20 million

Selecta Biosciences said Wednesday it has secured $20 million in equity funding from new and all of Selecta’s existing investors. Including the $20 million, Selecta said it has obtained a total of $78.6 Million in funding to date. Investors include Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, Rusnano, I2BF, Eminent Venture Capital and Leukon Investments. Selecta is a clinical stage biotechnology company that is developing a class of targeted antigen-specific immune therapies.


Bets pay off for venture funds in UC portfolio: VCJ

Last year saw several top performing funds in the University of California’s recent-vintage venture portfolio consolidate performance gains, as others continue to advanced, affiliate magazine Venture Capital Journal reported.

VC-backed Genocea Biosciences hires new CFO

Genocea Biosciences said Monday that it has named Jonathan Poole as chief financial officer. Previously, Poole worked at Shire where he served as senior vice president of finance for pipeline and technical operations. Based in Cambridge, Mass., Genocea Biosciences is a developer of T-cell vaccines. Genocea’s backers include Polaris Venture Partners, Lux Ventures, Skyline Ventures, Auriga Ventures, The Bill & Melinda Gates Foundation and Morningside Ventures.

Visterra closes Series A

Visterra, a developer of novel therapeutics to prevent and treat major infectious diseases, has secured $8.1 million in the final closing of its Series A financing round. This financing brings the total proceeds received to date from Series A to $34.2 million. Existing investors – Polaris Venture Partners, Flagship Ventures, Lux Capital, the Bill & Melinda Gates Foundation and Omega Funds – participated in the financing, as well as members of management and employees.

Apnex Medical Closes $10 Million Financing

Apnex Medical has secured financing totaling $10 million from New Enterprise Associates. The funds will be used to support the ongoing Apnex Clinical Study. Apnex develops medical devices aimed at helping people with sleep apnea. Other investors in the company include Domain Associates, Polaris Venture Partners and investor and Apnex chairman Michael Berman.

Boston Scientific to Acquire BridgePoint Medical

Boston Scientific Corporation is to acquire BridgePoint Medical. Minneapolis, Minnesota-based BridgePoint Medical was established in 2007 to develop and commercialize new technologies to treat challenging coronary artery disease. Investors include New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman.

BalconyTV Attracts First Institutional Funding Round

Global online music video channel BalconyTV–Music With A View has secured its first institutional funding from Polaris Venture Partners, Lerer Ventures and Greycroft Partners. Former MTV Networks CEO Judy McGrath will also join the company in an advisory role. BalconyTV was founded by three Dublin friends who began filming daily performances of new and up-and-coming […]

Athletes’ Performance Scores $22.5m Backing from ABS Capital

Athletes’ Performance, a provider of performance training, nutrition and physical therapy for athletes, military and corporations, has secured a $22.5 million investment from ABS Capital Partners. ABS Capital joins the Company’s initial investor Polaris Venture Partners. PRESS RELEASE Athletes’ Performance, a leading provider of integrated performance training, nutrition and physical therapy for elite athletes, military […]

Polaris To Earn 10x Return On Ascend Health Acquisition

Polaris Venture Partners anticipates a 10x return on its investment in Ascend Health Corp., according to a news report. Ascend, an operator of nine psychiatric inpatient facilities, said Monday it had agreed to sell itself to Universal Health Services for $500 million. The deal will bring Polaris $115 million when the merger closes in the […]

Infinite Power Solutions Closes $10m Series D

US clean technology company Infinite Power Solutions has completed a $10 million Series D financing. Existing financial investors Generation Investment Management, D. E. Shaw Ventures, Polaris Venture Partners and Core Capital Partners co-led the financing, which also included participation by Applied Ventures, the venture capital arm of Applied Materials, In-Q-Tel and two additional strategic investors. […]

Adimab Closes “Oversubscribed” Series F Round

Adimab, a Lebanon, New Hampshire-based maker of an antibody discovery platform, has raised what it’s calling an “oversubscribed” Series F financing. Neither terms nor investors are being disclosed. The company has already raised roughly $25 million since its 2007 founding, including from Polaris Venture Partners, Borealis Ventures, and Google Ventures. PRESS RELEASE: Adimab, LLC, a leader […]

AMS Promotes former Atlas Venture COO to President

Accounting Management Solutions, a provider of outsourced accounting, financial management, and consulting services has promoted Don MacKenzie to company president. MacKenzie joined the company in 2010 as chief operating officer and will retain this title. Jim Bourdon, founder of the company, will remain chief executive officer. Prior to joining AMS in 2010, MacKenzie served as […]

Gift-Giving Wantful Secures Series A

San Francisco-based gift-giving service Wantful has secured a $5.5 million series A investment. Led by Polaris Venture Partners, the round also includes funding from previous investors including Harrison Metal, Greylock Partners and Forerunner Ventures, as well as angel investors. PRESS RELEASE — Wantful, a leading gift-giving service focused on helping you give exceptional gifts for […]

Promedior Raises $21.5 Million

Promedior, a clinical stage biotechnology company has raised $21.5M in a first closing of a Series D financing round. The financing was led by a new investor, Fibrotec Ventures with participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This […]

Promedior Inks $21.5M

Malvern, Penn.-based Promedior Inc., a clinical stage biotechnology company developing therapeutics for fibroproliferative diseases, has held a $21.5 million first closing of its Series D round.  New investor Fibrotec Ventures led the round, which included existing shareholders Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This new round […]

Celgene to Acquire Avila Therapeutics

Summit, New Jersey-headquartered Celgene Corporation is to acquire Avila Therapeutics, a privately held biotechnology company. Avila is backed by Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners. PRESS RELEASE Celgene Corporation (NASDAQ: CELG) and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through […]

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget